Contact
searchSearch
HMP Global
Login

Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Alina Markova, MD, Memorial Sloan Kettering
Conference Coverage
Topical Ruxolitinib Shows Promise for Treatment of Patients With Chronic Cutaneous GVHD
01/11/2024
Alina Markova, MD
At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...
At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...
At the 65th ASH Annual Meeting...
01/11/2024
Oncology
Shernan G Holtan, MD, University of Minnesota
Conference Coverage
Selective Oral AURKA Inhibitor for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT
12/21/2023
Shernan Holtan, MD
At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...
At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...
At the 2023 ASH Annual Meeting,...
12/21/2023
Oncology
Daniel Wolff, MD, University Hospital Regensburg
Conference Coverage
AGAVE-201 Trial Finds Axatilimab Yields Durable Responses for R/R Chronic GVHD Treatment
12/18/2023
Daniel Wolff, MD
At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...
At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...
At the 2023 ASH Annual Meeting...
12/18/2023
Oncology
Shernan Holtan, MD
Videos
Latest Updates in Graft-Versus-Host Disease Prophylaxis
11/13/2023
Shernan Holtan, MD
Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.
Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.
Shernan Holtan, MD, explores the...
11/13/2023
Oncology
Shernan Holtan, MD
Videos
Frontline Treatment Options for Acute Graft-Versus-Host Disease
11/13/2023
Shernan Holtan, MD
Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.
Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.
Shernan Holtan, MD, explores...
11/13/2023
Oncology
Ernst Holler, MD
Videos
Exploring Mechanisms and Approaches for Graft-Versus-Host Disease Prophylaxis
09/05/2023
Ernst Holler, MD
Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.
Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.
Ernst Holler, MD, provides...
09/05/2023
Oncology
Ernst Holler, MD
Videos
Analyzing Risk Factors for Acute and Chronic Graft-Versus-Host Disease
09/05/2023
Ernst Holler, MD
Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.
Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.
Ernst Holler, MD, provides...
09/05/2023
Oncology
Benjamin Watkins, MD
Videos
Outcomes of Patients Treated With Abatacept for the Prevention of GVHD
08/22/2023
Benjamin Watkins, MD
Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.
Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.
Benjamin Watkins, MD, provides...
08/22/2023
Oncology
Benjamin Watkins, MD
Videos
Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease
08/22/2023
Benjamin Watkins, MD
Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.
Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.
Benjamin Watkins, MD, discusses...
08/22/2023
Oncology
Quiz
Skin Involvement and Disease Severity Estimates for Patients With Chronic Graft-Versus-Host Disease
08/09/2023
True or False: In a study conducted to identify whether the severity of skin involvement of patients with chronic graft-versus-host-disease (GVHD) is a prognostic marker, researchers found that patients with skin involvement, and particularly...
True or False: In a study conducted to identify whether the severity of skin involvement of patients with chronic graft-versus-host-disease (GVHD) is a prognostic marker, researchers found that patients with skin involvement, and particularly...
True or False: In a study...
08/09/2023
Oncology

Recent News

Conference Insider
Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD
07/01/2021
Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.
Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.
Ibrutinib given in combination...
07/01/2021
Oncology
News
ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD
05/10/2021
Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.
Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.
Belumosudil produces high...
05/10/2021
Oncology
News
Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD
06/23/2020
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.
In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.
In a phase 2 clinical trial,...
06/23/2020
Oncology
News
Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation
05/13/2020
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.
Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.
Ruxolitinib significantly...
05/13/2020
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use